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Background: Deintensification and less drug regimen (LDR) antiretroviral therapy (ART) 
strategies have proved to be effective in terms of maintaining viral suppression in human 
immunodeficiency virus (HIV)-positive patients, increasing tolerability, and reducing toxicity of 
antiretroviral drugs administered to patients. However, the economic impact of these strategies 
have not been widely investigated. The aim of the study is to evaluate the economic impact that 
ART LDR could have on the Italian National Health Service (INHS) budget.
Methods: A budget impact model was structured to assess the potential savings for the INHS by 
the use of ART LDR for HIV-positive patients with a 3 year perspective. Data concerning ART 
cost, patient distribution within different ARTs, and probabilities for patients to change ART 
on a yearly basis were collected within four Italian infectious diseases departments, providing 
ART to 13.7% of the total number of patients receiving ART in Italy.
Results: The LDR investigated (protease inhibitor-based dual and monotherapies) led to sav-
ings for the hospitals involved when compared to the “do nothing” scenario on a 3 year basis, 
between 6.7% (23.11 million €) and 12.8% (44.32 million €) of the total ART expenditures. 
The mean yearly cost per patient is reduced from 9,875 € in the do nothing scenario to a range 
between 9,218 € and 8,615 €. The use of these strategies within the four departments involved 
would have led to a reduction of ART expenditures for the INHS of between 1.1% and 2.1% 
in 3 years.
Conclusion: ART LDR simplification would have a significant impact in the reduction of 
ART-related costs within the hospitals involved in the study. These strategies could therefore 
be addressed as a sustainable answer to the public financing reduction observed within the 
INHS in the last year, allowing therapies to be dispensed without affecting the quality of the 
services provided.
Keywords: antiretroviral therapy, Italy, budget impact model, monotherapy, dual therapy, cost
Introduction
Progress in human immunodeficiency virus (HIV) treatment has resulted in up to nearly 
80% of patients reaching viral suppression (ie, HIV-1 RNA ,200 copies/mL), with 
reduction of mortality and morbidity of HIV.1 The increase of virological success is 
reflected in an improvement in clinical and immunological outcomes.
Once the goal of achieving undetectable HIV-1 RNA has been accomplished, 
most patients will likely continue treatment with the same antiretroviral regimen for 
many years, without any need for change. However, for some patients, there are often 
important, nonvirologic reasons to modify their antiretroviral regimen, such as for drug 
intolerance or the need to simplify the regimen.2–4 The perspective of long-term therapy 
and the availability of a high number of drugs with different toxicities and manageability 
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favors a tailor-made therapeutic course, aimed to ensure 
consistent virological suppression and also improve quality 
of life for the patients. In Italian guidelines, this strategy is 
called “antiretroviral therapy (ART) optimization.”
There are multiple potential reasons for considering a 
modification to the antiretroviral regimen of a virologically 
suppressed patient, including tolerability and toxicity5 and/or 
to preserve treatment options, avoid nucleoside reverse tran-
scriptase inhibitor (NRTI) toxicity, or even decrease treatment 
cost. Two main reasons to change antiretroviral treatment could 
be considered: reduction of number of antiretroviral drugs 
(the so called simplification or “deintensification,” leading to 
dual or monotherapy strategies) and reduction of daily dose, 
administration, and pill number (in a triple therapy strategy).
Physicians should discuss and evaluate with patients the 
potential risk/benefit ratio when establishing a new drug 
regimen to avoid long-term toxicities (preemptive switch) 
or drug interactions due to the need to treat other infections 
(tuberculosis, hepatitis B virus, hepatitis C virus, etc), to 
improve treatment adherence, to adjust for a planned preg-
nancy, or to accommodate a patient’s request.
When modification is necessary, the first goal, as stated 
above, is to maintain viral suppression. Maintaining an 
undetectable HIV-1 RNA is certainly possible with most 
triple drug antiretroviral combinations in patients who do 
not harbor drug-resistant HIV strains.
Several studies have investigated the clinical efficacy of 
protease inhibitor (PI)-based monotherapies.6–10
Arribas et al6 compared monotherapy with darunavir 
(DRV) + ritonavir (r) versus DRV/r plus two NRTIs in 
256 patients with viral load ,50 HIV-1 RNA copies/mL, 
showing monotherapy’s efficacy in being noninferior to the 
aforementioned triple therapy in a strict intention to treat 
analysis.
In a recent study,7 DRV + r monotherapy was compared 
with a DRV + r triple therapy strategy to maintain HIV-1 viral 
load suppression through a prospective, open-label, nonin-
feriority, randomized, 96-week trial. DRV + r monotherapy 
was assessed as durable and efficacious for maintaining 
virological suppression in HIV-1 patients.
Moreover the efficacy of r-boosted PI monotherapies was 
assessed through systematic review,8 identifying 22 studies. 
Through this review, the authors suggest that “the major-
ity of patients with prolonged viral suppression on highly 
active ART (HAART) can successfully be treated with PI 
monotherapy.”
The European AIDS Clinical Society guidelines 
recognize r-boosted PI monotherapy with once-daily 
DRV + r or twice-daily lopinavir (LPV)/r as possible options 
in patients who have intolerance to NRTI, or for treatment 
simplification.
Pulido et al9 compared the 48-week efficacy of LPV/r 
monotherapy with LPV/r plus two nucleosides in 205 patients 
with suppressed HIV replication in a randomized, open-label, 
investigator-initiated, noninferiority, multicenter clinical 
trial. The results showed LPV/r monotherapy with reintro-
duction of nucleosides as needed to be noninferior to LPV/r 
plus two nucleosides.
A recent study published by d’Arminio Monforte et al10 
confirmed in daily practice the efficacy and durability of 
LPV/r monotherapy in 228 patients with at least two con-
secutive HIV RNA #50 copies/mL in regimens including 
three or more drugs.
A further study published in 201211 confirms the clinical 
efficacy of PI-based monotherapies, retrospectively analyzing 
43 HIV-positive individuals who switched from a HAART 
regimen to either an atazanavir (ATV) + r or an ATV mono-
therapy while virologically suppressed for at least 6 months 
to evaluate the cumulative proportion of virological failures 
and the immunologic variation. The authors stated that the 
study results “may support a potential role for ATV in PI 
monotherapy simplification strategies and encourage further 
studies on this topic.” Despite these encouraging results, the 
use of ATV and ATV + r monotherapy has been challenged 
in different studies.12,13
In May 2013, the Italian Drug Agency approved the reim-
bursement of off-label monotherapy of DRV + r and LPV/r 
for HIV treatment, as per Italian law 648/96, based on the 
established use in clinical practice and scientific evidence. 
This agency decision is aligned with the most recent national 
guidelines14 concerning the use of antiretroviral drugs, rec-
ognizing the effectiveness of monotherapy.
The efficacy of dual therapy has been less investigated; 
however, available data foster encouragement for further 
investigations. Casado et al15 performed a retrospective cohort 
study on 44 HIV-infected patients on suppressive triple, 
 PI/r-based HAART, who discontinued one nucleoside analog 
due to toxicity and continued dual therapy with lamivudine 
(3TC) plus the PI/r. At baseline, patients had viral suppression 
for a median time of 794 days, while receiving DRV + r in 
25 cases, LPV/r in 14 cases, and ATV + r in five cases. The 
authors concluded that dual therapy with 3TC plus a boosted 
PI is a safe and effective simplification strategy in patients 
with toxicity to nucleoside analog.
In light of the results of the aforementioned study, the 
use of PI-based dual therapies with 3TC is considered a 
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feasible simplification strategy in the clinical pathway for 
HIV/acquired immunodeficiency syndrome (AIDS) in the 
Lazio region.16
Furthermore, the AtLaS study17 investigated the 48-week 
safety and efficacy of the simplification to ATV + r + 3TC 
in 40 HIV-positive patients on a stable ATV + r triple 
regimen, with viral load ,50 HIV-1 RNA copies/mL, CD4 
count .200 cells/mm3, and without previous treatment failure. 
The study results led the authors to state that this simplifica-
tion strategy was “apparently safe and associated with rare 
virological failure, without resistance selection.” However, the 
authors deem further investigation to be necessary.
Despite this evidence, the economic impact of simplifica-
tion ART strategies (PI-based dual therapies and PI-based 
monotherapies) from the payer point of view has not been 
properly investigated. The aim of the study presented in this 
article is to evaluate the economic impact that ART less drug 
regimens (LDRs) could have on the Italian National Health 
Service (INHS) budget.
Material and methods
A budget impact model was structured to assess the potential 
savings for the INHS in the use of ART LDRs for HIV-
positive patients with a 3-year perspective. This time horizon 
was chosen as suggested by budget impact international 
guidelines.18
The model was used to simulate five different scenarios: 
one that does not take into consideration any therapy simpli-
fication and four that consider different LDR simplification 
strategies (each of the last four scenarios was compared with 
the “do nothing” scenario to assess the differential cost for 
ART). LDRs were selected by the directors of six infectious 
diseases departments/wards of five Italian hospitals located 
in Milan, Rome, and Turin.
The total number of patients treated with ART was iden-
tified in the four hospitals involved (San Raffaele Hospital 
Specialist Clinic, “Luigi Sacco” Hospital, The National 
Institute for Infectious Disease “L Spallanzani” Specialist 
Clinic, Policlinico Tor Vergata) on December 31, 2012, and 
among them, the number of patients treated with PI-based 
treatments and with tenofovir (TDF)/emtricitabine (FTC) + 
efavirenz (EFV) or TDF/FTC/EFV. Further information on 
the number of patients following PI-based dual therapies 
and PI-based monotherapies was collected. The infectious 
diseases departments involved in the study in 2012 provided 
ART to 13.7% of the total number of patients receiving ART 
in Italy, as calculated by reprocessing data published by the 
Italian National Institute of Health.19
The model considers different therapies to be assigned to 
patients: triple therapies with PI, TDF/FTC + EFV or TDF/
FTC/EFV, PI-based monotherapies (LPV/r, ATV + r, or DRV 
+ r), and PI-based dual therapies (3TC + LPV/r, 3TC + DRV 
+ r, 3TC + ATV + r, or 3TC + ATV). For dual therapies, only 
3TC was considered as backbone since it was the only generic 
drug on the market in Italy at the time of the analysis, and in 
considering LDR simplification strategies, it could maximize 
the advantage for the INHS.
In year 0, patients were assigned to different therapies as 
observed in the wards involved in the study. The distribution 
of patients within the therapies is reported in Table 1.
The hypotheses of the different LDR simplification sce-
narios are reported below.
scenario one
Each cycle, one-third of the patients in PI-based triple 
therapy addressed as eligible for PI-based monotherapy and 
PI-based dual therapy are moved to PI-based monotherapy 
and PI-based dual therapy.
scenario two
In the first cycle, all patients in PI-based triple therapy 
addressed as eligible for PI-based monotherapy and PI-based 
dual therapy are moved to PI-based monotherapy and PI-
based dual therapy.
scenario three
Each cycle, one-third of the patients in PI-based triple therapy 
and on TDF/FTC + EFV or TDF/FTC/EFV addressed as 
Table 1 Patient distribution within the different therapeutic opti-
ons in the model at time 0
Total number of patients 11,269
Patients treated with triple PI-based treatments 4,763
Patients taking TDF/FTC + EFV or TDF/FTC/EFV 2,014
Patients taking 3TC + DRV + r 300 mg (1) + 400 mg (2)/100 mg 
(1)
52
Patients taking 3TC + DRV + r 150 mg (1) + 600 mg (1)/100 mg 
(1) BiD
4
Patients taking 3TC + LPV/r 300 mg QD + 400 mg/100 mg BiD 68
Patients taking 3TC + ATV + r 300 mg (1) + 300 mg (1)/100 mg 53
Patients taking 3TC + ATV 300 mg QD + 400 mg QD 33
Patients taking DRV + r 400 mg (2) + 100 mg (1) 221
Patients taking DRV + r 600 mg (1×2) + 100 mg (1×2) 8
Patients taking LPV/r 400 mg/100 mg BiD 157
Patients taking ATV + r 300 mg (1) + 100 mg (1) 103
Patients taking other treatments 3,793
Note: numbers in parentheses refer to the number of tablets per day.
Abbreviations: 3TC, lamivudine; ATV, atazanavir; BID, twice a day; DRV, darunavir; 
EFV, efavirenz; FTC, emtricitabine; LPV, lopinavir; PI, protease inhibitor; QD, once 
a day; r, ritonavir; TDF, tenofovir.
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eligible for PI-based monotherapy and PI-based dual therapy are 
moved to PI-based monotherapy and PI-based dual therapy.
scenario four
In the first cycle, all patients in PI-based triple therapy and on 
TDF/FTC + EFV or TDF/FTC/EFV addressed as eligible for 
PI-based monotherapy and PI-based dual therapy are moved 
to PI-based monotherapy and PI-based dual therapy.
The structure of the model is presented in Figure 1.
In each cycle, a number of patients equal to 3% of the total 
number of patients of the previous cycle enter the model (1.5% 
in PI-based triple therapy and 1.5% in TDF/FTC + EFV or 
TDF/FTC/EFV), and 1% of the total number of patients of 
the previous cycle exit the model due to death (0.33% from 
PI-based triple therapy, 0.33% from TDF/FTC + EFV or 
TDF/FTC/EFV, 0.33% from other therapies).
Every cycle, patients could modify their therapy based 
on the hypothesis of each scenario or continue to use the 
same therapy as the previous cycle. The probability to 
change therapy was assessed by collecting data within the 
six wards involved and considering the number of patients in 
treatment with different therapies on January 1, 2012 and on 
December 31, 2012. The percentage of patients still using the 
same therapy was considered the probability to continue to 
use the same therapy, not switching to PI-based triple therapy. 
The percentage related to monotherapies and dual therapies 
are presented in Table 2.
The clinical criteria to consider patients eligible for PI-based 
monotherapy were the following: HIV-RNA ,50 copies/mL; 
CD4 count .200 cells/mm3; virologically controlled for at 
least 12 months; nadir CD4 count .100 cells/mm3; no PI resis-
tance mutations. Clinical criteria to consider patients eligible 
for PI-based dual therapy were: HIV-RNA ,50 copies/mL; 
virologically controlled for at least 12 months; no PI resistance 
mutations.
Patients eligible for monotherapy were at the same time 
eligible for dual therapy; in this case, a monotherapy regi-
men was preferred.
The patient distribution in the three most administered 
PI-based triple therapies is reported in Table 3. The annual 
cost for this category of patients was considered to be the 
weighted mean of the three therapies.
TDF/FTC + EFV or
TDF/FTC/EFV Other therapies  
New patients   
Death  PI-based
monotherapya
PI-based dual
therapyb
PI-based triple
therapy   
Figure 1 structure of the budget impact model.
Notes: aPI-based monotherapies are DRV + r 400 mg (2) + 100 mg (1); DRV + r 600 mg 
(1×2) + 100 mg (1×2); LPV/r 400 mg/100 mg BID; ATV + r 300 mg (1) + 100 mg (1); 
bPI-based dual therapies are 3TC + DRV + r 300 mg (1) + 400 mg (2)/100 mg (1); 
3TC + DRV + r 150 mg (1) + 600 mg (1)/100 mg (1) BiD; 3TC + LPV/r 300 mg 
QD + 400 mg/100 mg BiD; 3TC + ATV + r 300 mg (1) + 300 mg (1)/100 mg; 3TC + 
ATV 300 mg QD + 400 mg QD. arrows represent the possible therapy changes for 
patients in every yearly cycle.
Abbreviations: 3TC, lamivudine; ATV, atazanavir; BID, twice a day; DRV, darunavir; 
EFV, efavirenz; FTC, emtricitabine; LPV, lopinavir; PI, protease inhibitor; QD, once 
a day; r, ritonavir; TDF, tenofovir.
Table 2 Percentage probability for patients using monotherapies 
and dual therapies to continue to use the same therapy in the 
following cycle, as assessed from data collected in the period 
January 1, 2012–December 31, 2012 in the wards involved in 
the analysis
Therapy Patients still using the 
same therapy after 1 year
3TC + DRV + r 91.9%
3TC + LPV/r 90.5%
3TC + ATV + r 83.2%
DRV + r 92.1%
LPV/r 74.1%
ATV + r 88.7%
Abbreviations: 3TC, lamivudine; ATV, atazanavir; DRV, darunavir; LPV, lopinavir; 
r, ritonavir.
Table 3 Patient distribution within protease inhibitors-based 
triple therapies
Therapy Percentage 
of patients
TDF/FTC + ATV + r (600/300 mg + 300 mg + 100 mg) 48.7%
TDF/FTC + DRV + r (600/300 mg + 800 mg + 100 mg) 28.2%
TDF/FTC + LPV/r (600/300 mg + 400/100 mg ×2) 23.1%
Abbreviations: ATV, atazanavir; DRV, darunavir; FTC, emtricitabine; LPV, 
lopinavir; r, ritonavir; TDF, tenofovir.
Table 4 Total aRT costs in year 0, divided by treatment typology
Therapy Cost (€) % of total cost
PI-based triple therapies 46,399,663 41.8%
PI-based dual therapies 1,011,970 0.9%
PI-based monotherapies 2,191,971 2.0%
TDF/FTC + EFV or TDF/FTC/EFV 16,008,736 14.4%
Other therapies 45,476,441 40.9%
Total 111,088,781 100%
Abbreviations: ART, antiretroviral therapy; EFV, efavirenz; FTC, emtricitabine; PI, 
protease inhibitor; TDF, tenofovir.
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The costs of ART refer to 2013 and are value added tax 
inclusive, as reported in the Lombardy Region HIV/AIDS 
Clinical Diagnostic Pathway.20
The cost of ART for each patient in the “other therapies” 
category was calculated by subtracting the costs related to 
PI-based therapies, TDF/FTC + EFV, and TDF/FTC/EFV 
from the costs of all the therapies administered to patients 
within the wards involved in the study, and dividing it by 
the number of patients treated in each ward not with the 
aforementioned therapies (PI-based therapies, TDF/FTC + 
EFV, and TDF/FTC/EFV).
Results
The costs to treat the sample per treatment typology in year 0 
are reported in Table 4, and the total cost to treat the sample 
and the cost per patient in each scenario are reported in 
Table 5. The difference in terms of 3-year cost between the 
do nothing scenario and the other scenarios are −6.7% for 
scenario one, −9.5% for scenario two, −9.0% for scenario 
three, and −12.8% for scenario four.
On a 3-year basis, the mean yearly cost per patient is 
reduced from 9,875 € in the do nothing scenario to 9,218 € 
in scenario one, 8,936 € in scenario two, 8,986 € in scenario 
three, and 8,615 € in scenario four.
The 3-year impact on the INHS of the LDR simplification 
strategies presented, considered as the difference between 
the “do nothing scenario” and each LDR simplification 
scenario, is between −23.11 million € and −44.32 million 
€, with mean yearly savings between −7.70 million € and 
−14.77 million €.
Considering the last available data on the total ART expen-
diture in Italy, 689.4 million € in 2012,21 the implementation of 
the LDR simplification strategies presented above within the 
hospitals involved in the study would lead to a reduction of 
the ART expenditures at a national level, considering the mean 
3-year reduction is between −1.1% and −2.1%.
Discussion
ART LDR would have a significant impact in the reduc-
tion of ART-related costs within the hospitals involved 
in the study. Considering the encouraging results of 
the clinical studies presented in the background and 
the public financing reduction of the INHS, the need to 
identify strategies that could reduce the per capita cost to 
provide therapies not affecting the quality of the services 
provided could be addressed by ART LDR simplification 
strategies.
In the literature, this topic was addressed mainly through 
head to head cost effectiveness studies; a budget impact 
analysis taking the INHS point of view was lacking. The only 
such analysis in the literature is a 2014 study by Angeletti 
et al,22 whose objective, however, was the assessment of 
different cost saving strategies. Among these, the switch 
of 20%–40% of stable first and second line patients from 
PI-based triple therapies to PI-based monotherapies was 
estimated to lead to yearly savings for the Health Service of 
the Lazio region of between 1.0 million € and 1.9 million €, 
considering the total cost for the Regional Health Service 
to provide care to patients (considering antiretroviral drugs, 
nonantiretroviral drugs, hospital admissions, out-patient 
care, and laboratory tests). These amounts represent 0.6% 
and 1.3%, respectively, of the yearly regional cost of care 
of HIV-positive patients.
Conclusion
The analysis presented shows the potential savings that LDR 
simplification strategies could lead to for the INHS, if applied 
widely. The main strength of the analysis is related to the data 
considered, which reflect the real clinical practice of the wards 
involved. PI-based dual therapies and monotherapies were 
taken into consideration in the analysis, including the ones 
considered off-label (ATV + r monotherapy) when detected 
within the hospitals. The main weakness of the model is that 
it does not take into consideration the costs of therapy switch, 
and considers only ART costs. Moreover, we assumed that 
all the patients eligible for a LDR simplification are switched 
to a dual therapy or monotherapy within the 3-year time 
horizon considered.
In light of the potential savings that emerged in the 
analysis, the switch of eligible patients receiving PI-based 
Table 5 Yearly and total aRT cost and per capita aRT cost for each scenario
Scenario Total ART cost to treat the sample (€) Per capita ART cost (€)
Year 1 Year 2 Year 3 3 years total Year 1 Year 2 Year 3 3 years mean
Do nothing 113,472,398 115,800,466 118,098,395 347,371,260 9,872 9,877 9,876 9,875
scenario one 109,236,201 107,932,762 107,089,570 324,258,533 9,503 9,206 8,955 9,218
scenario two 100,763,807 104,900,243 108,677,786 314,341,836 8,766 8,947 9,088 8,936
scenario three 107,659,058 105,122,653 103,327,709 316,109,420 9,366 8,966 8,640 8,986
scenario four 96,032,378 101,201,345 105,822,532 303,056,254 8,355 8,632 8,849 8,615
Abbreviation: aRT, antiretroviral therapy.
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triple, TDF/FTC + EFV, or TDF/FTC/EFV therapies should 
be regarded as a feasible and cost-saving strategy.
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